Adenoviruses are known to reactivate in immunocompromised patients alongside the ability to persist in lymphoid tissues. This greatly complicates their management as well as increases the necessity of research directed towards effective vaccines and therapies. Our team provides a range of services relating to the development of vaccines and other therapies for adenovirus infections.
Introduction to Adenovirus Infection
Adenoviruses (AdVs) are potent and rather heterogeneous viruses of double stranded DNA which cause a variety of ailments in humans. These viruses are responsible for respiratory tract infections, conjunctivitis, gastroenteritis and even severe infections in immunocompromised individuals. Infections are spread via respiratory droplets, touched contaminated surfaces, and fecal-oral route. Commonly they are mild respiratory infections, but in extremes like children and immunocompromised people they can lead to severe consequences.
Fig.1 Tropism of human adenoviruses with associated clinical diseases in various organ systems. (Shieh W. J., et al., 2022)
Vaccine Development for Adenovirus Infection
Vaccines development aimed against adenovirus infections continues to be a relevant research area where the need to induce immunogenic responses that prevent or treat disease is undergoing. There are a number of vaccines under consideration:
Live Attenuated Vaccines
Such vaccines employ live viruses that have been attenuated so that they do not induce the disease, and have been employed in the military as protection against respiratory infections due to AdV serotypes 4 and 7.
Recombinant Vector Vaccines
These vaccines purport to evoke an immune response whilst being delivered using harmless viruses, and in doing so, manage to refrain from causing any disease.
Subunit Vaccines
Such vaccines are deemed safe, as these do not contain any viral infection, due to the fact that they contain purified portions of viral infections such as proteins or sugars
DNA Vaccines
Adenovirus antigens plasmids are actively used in this type of vaccine, which stands on the modern edge of racel biology and therapy and can recruit cellular as well as humoral immune mechanisms.
mRNA Vaccines
mRNA vaccines are a unique technique in valorization of vaccines which enables the development of an immune response in the host cell by transcribing the genetic information for the required adenovirus antigens.
Inactivated Vaccines
There are efforts made in developing inactivated vaccines against adenoviruses, notwithstanding, they remain a rarity. Such vaccines necessitate the use of particle adenovirus that has been killed with the intention of invoking an immune reaction without an actual disease.
Therapeutics Development for Adenovirus Infection
Cytosine nucleotide that acts as a replication inhibitor, cidofovir is said to have some regard against in vitro adenovirus. It is off label use to treat severe infections through inhibition of viral dna. Other nucleoside analogs like, brincidofovir, are structural alterations of nucleosides and are capable of being incorporated into the viral dna, and as such halting the viral replication. We are able to offer you antivirals and adeno virus infection immunotherapy as well. We have our one stop solution to your problems that you could access via the link below.
Our Services
In collaboration with a cross functional team of specialized professionals; we integrate advanced studies to practical uses in order to create and implement advanced adenoviral infection vaccine and therapeutics development projects. Our scope includes:
Disease Models
- Acute Respiratory Disease Models with Murine Adenovirus
- Adenovirus Infection Pig Models: mimic interstitial pneumonia in humans
- Adenovirus Keratoconjunctivitis New Zealand White Rabbit Models
- Adenovirus-C5 Lung and Ocular Infection Cotton Rat Models
Through our integrated approach, we aim to accelerate the discovery and development of effective vaccines and therapies against adenovirus infections. If you are interested in our services, please feel free to contact us.
References
- Shieh, Wun-Ju. "Human adenovirus infections in pediatric population-an update on clinico-pathologic correlation." Biomedical journal 45.1 (2022): 38-49.
- Lynch III, Joseph P., and Adriana E. Kajon. "Adenovirus: epidemiology, global spread of novel serotypes, and advances in treatment and prevention." Seminars in respiratory and critical care medicine. Vol. 37. No. 04. Thieme Medical Publishers, 2016.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
